Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 93,456 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 93,456 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $16.94, for a total transaction of $1,583,144.64. Following the transaction, the insider directly owned 418,557 shares in the company, valued at $7,090,355.58. This represents a 18.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Relay Therapeutics Trading Up 3.4%

Shares of RLAY stock opened at $18.03 on Thursday. The stock has a market cap of $3.45 billion, a P/E ratio of -11.49 and a beta of 1.75. Relay Therapeutics, Inc. has a 1 year low of $3.03 and a 1 year high of $18.83. The stock has a 50 day simple moving average of $14.40 and a 200 day simple moving average of $11.04.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.58 million. Analysts forecast that Relay Therapeutics, Inc. will post -1.55 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on RLAY shares. Citizens Jmp upped their price objective on shares of Relay Therapeutics from $19.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 20th. The Goldman Sachs Group raised their target price on shares of Relay Therapeutics from $13.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Wells Fargo & Company boosted their target price on shares of Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Oppenheimer upped their price target on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Finally, Barclays increased their price target on shares of Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Relay Therapeutics presently has an average rating of “Buy” and a consensus price target of $23.30.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Torren Management LLC acquired a new position in Relay Therapeutics during the fourth quarter worth about $30,000. KBC Group NV acquired a new stake in shares of Relay Therapeutics in the 1st quarter valued at approximately $34,000. Smartleaf Asset Management LLC boosted its stake in shares of Relay Therapeutics by 288.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after purchasing an additional 3,287 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Relay Therapeutics during the 4th quarter valued at approximately $46,000. Finally, Captrust Financial Advisors bought a new stake in shares of Relay Therapeutics during the 2nd quarter valued at approximately $49,000. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.